112940-60-0Relevant academic research and scientific papers
RADIOLABELED COMPOUNDS
-
, (2019/07/13)
The present invention relates to radiolabeled compounds of formula (I) wherein either A, B, R1, R2, is labeled with a radionuclide selected from 3H, 11C and 18F and its use for imaging alpha synuclein and/or Abeta deposits in mammals.
Benzodiazepines as potent and selective bradykinin B1 antagonists
Wood, Michael R.,Kim, June J.,Han, Wei,Dorsey, Bruce D.,Homnick, Carl F.,DiPardo, Robert M.,Kuduk, Scott D.,MacNeil, Tanya,Murphy, Kathy L.,Lis, Edward V.,Ransom, Richard W.,Stump, Gary L.,Lynch, Joseph J.,O'Malley, Stacey S.,Miller, Patricia J.,Chen, Tsing-Bau,Harrell, Charles M.,Chang, Raymond S. L.,Sandhu, Punam,Ellis, Joan D.,Bondiskey, Peter J.,Pettibone, Douglas J.,Freidinger, Roger M.,Bock, Mark G.
, p. 1803 - 1806 (2007/10/03)
Antagonism of the bradykinin B1 receptor was demonstrated to be a potential treatment for chronic pain and inflammation. Novel benzodiazepines were designed that display subnanomolar affinity for the bradykinin B1 receptor (Ki = 0.59 nM) and high selectivity against the bradykinin B2 receptor (Ki > 10 nM). In vivo efficacy, comparable to morphine, was demonstrated for lead compounds in a rodent hyperalgesia model.
